Main Article Content

Ashish B. Gulwe
Ebube S.Chidera
Awote O.Kayode
Ajay N.Ambhore


Alzheimer’s disease (AD), Bioactive compounds, Molecular Docking, Galantamine, Resveratrol, Donepezil, PyRx, Discovery studio, Binding affinity


Alzheimer’s disease (AD) is a complex neurodegenerative disease that is characterized by the accumulation of amyloid-beta(Aβ) peptides in the brain. It is the most common type of dementia which begins with mild memory loss and leads to severe decline in one’s ability to hold adequate conversation and response with the environment. β-secretase-1(BACE-1) is a key enzyme involved in the production of Aβ peptides, making it an attractive target for drug discovery in AD treatment. Herein, this study aimed to investigate the anti-alzheimer’s potential of selected bioactive compounds against BACE-1 protein.Molecular docking was employed using PyRx and Biovia Discovery Studio software to predict potential selected bioactive antagonists and non-covalent interactions between the selected ligands, standard drugs and the target protein. BACE-1 target protein was docked with ligands namely; Tacrine, Harmine, Coumarin, Berberine, Indole, Resveratrol, Huperzine, 3-chloro-R(2),C(6)-bis(4fluorophenyl)-3-methylpipiridin-4-one (CFMP), and the standard alzheimer’s drugs namely; Donepezil and Galantamine after which the ligand with the best binding affinity was determined. The docking result from this study revealed Resveratrol as the ligand with the best binding affinity when docked with the selected Alzheimer’s target proteins.

Abstract 102 | pdf Downloads 54


1. Błaszczyk JW. Pathogenesis of Dementia. International Journal of Molecular Sciences. 2022 Dec 29;24(1):543
2. Vogt AC, Jennings GT, Mohsen MO, Vogel M, Bachmann MF. Alzheimer’s Disease: A Brief History of Immunotherapies Targeting Amyloid β. International journal of molecular sciences. 2023 Feb 15;24(4):3895.
3. Rodgers PA. Design research for change: caring for people living with dementia: introduction. InDesign for People Living with Dementia 2022 May 5 (pp. 1-12). Routledge.
4. Srivastav Y, Prajapati A, Prajapati A, Kumar M, Siddiqui MA. An investigation into Alzheimer's disease, its current treatments, biomarkers, and risk factors.
5. De Leake KR. Dementia, Medications and Non-Pharmacological Approaches.
6. Lau V, Ramer L, Tremblay MÈ. An aging, pathology burden, and glial senescence build-up hypothesis for late onset Alzheimer’s disease. Nature Communications. 2023 Mar 25;14(1):1670.
7. Ghazal TM, Abbas S, Munir S, Khan MA, Ahmad M, Issa GF, Zahra SB, Khan MA, Hasan MK. Alzheimer Disease Detection Empowered with Transfer Learning. Computers, Materials & Continua. 2022 Mar 1;70(3).
8. Madnani RS. Alzheimer’s disease: a mini-review for the clinician. Frontiers in Neurology. 2023 Jun 22;14:1178588.
9. Buccellato FR, D’Anca M, Fenoglio C, Scarpini E, Galimberti D. Role of oxidative damage in Alzheimer’s disease and neurodegeneration: From pathogenic mechanisms to biomarker discovery. Antioxidants. 2021 Aug 26;10(9):1353.
10. Liu PP, Xie Y, Meng XY, Kang JS. History and progress of hypotheses and clinical trials for Alzheimer’s disease. Signal transduction and targeted therapy. 2019 Aug 23;4(1):29.
11. Ju Y, Tam KY. Pathological mechanisms and therapeutic strategies for Alzheimer’s disease. Neural Regeneration Research. 2022 Mar;17(3):543.
12. Hirshfeld surface analysis, Interaction energy calculation and spectroscopical study of 3-chloro-3-methyl-R(2),C(6)-bis(p-tolyl)piperidin-4-one using DFT approaches sept,2021
13. Synthesis, identification and molecular docking studies of N-functionalized piperidine derivatives linked to 1,2,3-triazole ring June 2020
14. Synthesis, Crystal Structure, DFT Calculations and Hirshfeld Surface Analysis of 3-Chloro-2,6-Bis(4-Chlorophenyl)-3-Methylpiperidin-4-One June 2021
15. Design, molecular docking analysis of an anti-inflammatory drug, computational analysis and intermolecular interactions energy studies of 1-benzothiophene-2-carboxylic acid Oct 2020
16. Properties and Reactivities of Niclosamide in Different Media, a Potential Antiviral to Treatment of COVID-19 by Using DFT Calculations and Molecular Docking June 2020
17. New oxadiazole bearing thiosemicarbazide analogues: Synthesis, anti-Alzheimer inhibitory potential and their molecular docking study H Ullah, F Fayyaz, A Hussain, F Rahim, S Hayat… - Chemical Data …, 2022 – Elsevier
18. Synthesis, biological evaluation and molecular docking study of oxindole based chalcone analogues as potent anti-Alzheimer agents M Taha, H Sadia, F Rahim, MI Khan, S Hayat… - Journal of Molecular …, 2023 – Elsevier
19. Applications of In Silico Methodologies in Exploring the Inhibitory Potentials of Fisetin on MMP-8 and MMP-13 in Colorectal Cancer Progression MD Samuel, O Bimpe, KR Ilesanmi, OO Jude - Int J Drug Dev & Res, 2017 -
20. Identification of BACE-1 Inhibitors against Alzheimer’s Disease through E-Pharmacophore-Based Virtual Screening and Molecular Dynamics Simulation Studies: An Insilco Approach